A transdermal skin patch EMSAM (selegiline) has received the FDA nod for treating melancholy and depression. The most significant aspect about selegiline is lesser side-effects in comparison to orally taken antidepressants that could revolutionize the manner in which major depression is treated.
Formerly employed for treatment of Parkinson’s disease and depression signs like anxiousness, panic attack, over sleepiness or heightened craving for foods, selegeline is a MAOI. MAOI belongs to an older category of antidepressant medicines that are classically employed as a final option. When consumed via oral course, the associated side effects of these medicines have a tendency of causing life-menacing hypertension as well other commonly noted side-effects [...]
Novel, FDA-Approved Transdermal Skin Patch EMSAM to Treat Depression
